Found: 5
Select item for more details and to access through your institution.
Changes in Body Composition with Ritonavir-Boosted and Unboosted Atazanavir Treatment in Combination with Lamivudine and Stavudine: A 96-Week Randomized, Controlled Study.
- Published in:
- Clinical Infectious Diseases, 2009, v. 48, n. 9, p. 1323, doi. 10.1086/597776
- By:
- Publication type:
- Article
A Pharmacokinetic Bioequivalence Study Comparing Sublingual Riluzole (BHV‐0223) and Oral Tablet Formulation of Riluzole in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 4, p. 476, doi. 10.1002/cpdd.747
- By:
- Publication type:
- Article
Clinical Significance of Hyperbilirubinemia Among HIV-1-Infected Patients Treated with Atazanavir/Ritonavir Through 96 Weeks in the CASTLE Study.
- Published in:
- AIDS Patient Care & STDs, 2012, v. 26, n. 5, p. 259, doi. 10.1089/apc.2011.0092
- By:
- Publication type:
- Article
Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study.
- Published in:
- PLoS ONE, 2010, v. 5, n. 6, p. 1, doi. 10.1371/journal.pone.0010952
- By:
- Publication type:
- Article
Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week Results.
- Published in:
- Clinical Infectious Diseases, 2007, v. 44, n. 11, p. 1484, doi. 10.1086/517497
- By:
- Publication type:
- Article